Posted on 2/2/14

fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
SurfKY News
Information provided by the United States Food and Drug Administration your social media marketing partner

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

Madisonville Police Department Reports Released - Oct. 8, 2015

MADISONVILLE, Ky. (10/8/15) — The Madisonville Police Department released the following reports Thursday, Oct. 8.… Read More

Rider Killed in Motorcycle Collision with Bucket Truck

DAVIESS COUNTY, Ky. (10/9/15) — A 27-year-old Owensboro man was killed this morning during a two-vehicle collision on… Read More

Most Read This Week

October 06, 2015 4857

County Passes Occupational Tax Ordinance

by Doreen Dennis, SurfKY News
October 07, 2015 4750

Alleged Attempt to Hide Meth in Doughnuts Results…

by SurfKY News
October 05, 2015 4095

Four Charged with Drug Offenses after Motel…

by SurfKY News
October 06, 2015 3790

Dawson Man Charged with Cultivating Marijuana,…

by SurfKY News
October 07, 2015 3256

Vehicle Overturns during Two-Car Collision

by Rita Dukes Smith, SurfKY News Director

Most Read This Month

September 16, 2015 13404

Mining Accident Fatality - Update

by Doreen Dennis, SurfKY News
September 30, 2015 11461

Dawson Woman Dead After Princeton Factory…

by SurfKY News

Stories Trending Now

October 08, 2015 1429

Madisonville Police Department Reports Released -…

by SurfKY News
October 08, 2015 1261

Hopkins County Health Department Food Scores Thru…

by SurfKY News
October 08, 2015 1206

Local Pastor's Son Filming Documentary about…

by Doreen Dennis, SurfKY News
October 08, 2015 935

Work Zone Lane Restriction on Pennyrile Pkwy Set…

by SurfKY News
October 08, 2015 840

Democratic Candidate for Governor Jack Conway…

by SurfKY News
October 08, 2015 816

Registration for Free 'Project Hire Kentucky'…

by SurfKY News
October 09, 2015 770

Travis Ipox Appointed as New Agency Manager of…

by SurfKY News
October 09, 2015 744

Hopkins District Court Fines Handed Down

by SurfKY News
October 08, 2015 657

Guns - Stopping That One Person

by SurfKY News
October 08, 2015 619

UPDATE: Mortons Gap Boil Water Advisory Lifted

by SurfKY News